NasdaqCM - Nasdaq Real Time Price USD

Kronos Bio, Inc. (KRON)

0.6750

+0.0035

+(0.52%)

At close: May 30 at 4:00:02 PM EDT

0.6605

-0.01

(-2.15%)

After hours: May 30 at 5:37:16 PM EDT

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock (“Kronos

GlobeNewswire last month

KRON
+0.52%
Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023)

Kronos Bio ( NASDAQ:KRON ) Full Year 2024 Results Key Financial Results Net loss: US$86.1m (loss narrowed by 24% from...

Simply Wall St. 2 months ago

KRON
+0.52%
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial Results Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-c

GlobeNewswire 2 months ago

KRON
+0.52%
Kronos Bio Insider Ups Holding By 36% During Year

Insiders were net buyers of Kronos Bio, Inc.'s ( NASDAQ:KRON ) stock during the past year. That is, insiders bought...

Simply Wall St. 3 months ago

KRON
+0.52%
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 4 months ago

KRON
+0.52%
Discover 3 US Penny Stocks With Market Caps Over $40M

As the U.S. stock market reaches new heights with record closings for the S&P 500 and Nasdaq, investors are exploring diverse opportunities beyond large-cap tech stocks. Penny stocks, while often associated with smaller or newer companies, remain a relevant area for those seeking unique investment possibilities. Despite their vintage-sounding name, these stocks can offer surprising value when backed by strong financials, providing potential for significant returns and stability.

Simply Wall St. 5 months ago

KRON
+0.52%

BWEN

PMVP
Kronos Bio announces interim CEO and workforce cuts of 83%

Norbert Bischofberger will step down from his position as president and CEO on 3 December 2024 but remain on the board of directors.

Pharmaceutical Technology 5 months ago

KRON
+0.52%
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul

Kronos Bio, Inc. (NASDAQ:KRON) shares are trading higher on Wednesday in the premarket session. The firm announced significant leadership and operational changes. Deborah Knobelman has been appointed as the company's new President and Interim Chief Executive Officer, effective December 3, 2024. Knobelman will take on the role of principal executive, financial, and accounting officer, succeeding Norbert Bischofberger, who will step down from his position as President and CEO. Bischofberger will c

Benzinga 6 months ago

KRON
+0.52%
Kronos Bio Announces CEO Transition and Reduction in Force

– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Ch

GlobeNewswire 6 months ago

KRON
+0.52%
Kronos, Idorsia plan layoffs; PTC shelves ALS drug

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.

BioPharma Dive 6 months ago

IDIA.SW

PTCT

KRON
+0.52%
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations

Kronos Bio ( NASDAQ:KRON ) Third Quarter 2024 Results Key Financial Results Net loss: US$14.1m (loss narrowed by 55...

Simply Wall St. 6 months ago

KRON
+0.52%
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today highlighted preclinical data fr

GlobeNewswire 6 months ago

KRON
+0.52%
Kronos mulls ‘strategic alternatives’ after axing cancer drug development

The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable risk-benefit profile”.

Pharmaceutical Technology 6 months ago

KRON
+0.52%
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates

Kronos Bio (KRON) delivered earnings and revenue surprises of 11.54% and 35.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

KRON
+0.52%
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio Board of Directors has approved plan to evaluate strategic alternatives to maximize stockholder value – – Kronos Bio’s additional pipeline assets include preclinical p300 KAT inhibitor programs in oncology and autoimmune disease – — $124.9 million cash, cash equivalents, and investments as of September 30, 2

GlobeNewswire 6 months ago

KRON
+0.52%
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place on Monday, December 9, 2024 – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today announced that it

GlobeNewswire 6 months ago

KRON
+0.52%
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today announced preclinical data from its p300 KAT inhibitor program for human papillomavirus (HPV)-driven tum

GlobeNewswire 7 months ago

KRON
+0.52%
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – – Poster presentation taking place on Thursday, October 24, 2024 – SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today announced t

GlobeNewswire 7 months ago

KRON
+0.52%
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks – – Preclinical data for KB-7898 will be presented at ACR Convergence 2024 – SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune d

GlobeNewswire 7 months ago

KRON
+0.52%
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases – – Oral presentation taking place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST – SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers

GlobeNewswire 8 months ago

KRON
+0.52%

Performance Overview

Return	KRON	S&P 500 (^GSPC)
YTD	-28.95%	+0.51%
1-Year	-13.57%	+12.92%
3-Year	-81.71%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kronos Bio, Inc. (KRON)

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023)

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Kronos Bio Insider Ups Holding By 36% During Year

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Discover 3 US Penny Stocks With Market Caps Over $40M

Kronos Bio announces interim CEO and workforce cuts of 83%

Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos, Idorsia plan layoffs; PTC shelves ALS drug

Kronos Bio Third Quarter 2024 Earnings: Beats Expectations

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Kronos mulls ‘strategic alternatives’ after axing cancer drug development

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

Performance Overview